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before, although it has been suggested that assuming a Pra value of
5 mm Hg results in insignificant differences in CFI (5). In
contrast, our findings show that substantial errors occur when right
atrial pressure is assumed to be a fixed value. It is interesting to
note that Seiler et al. (6) found a better correlation between
Doppler- and pressure-derived CFI when a measurement of
central venous pressure was included, as compared with those
calculations where venous pressure was assumed to be 5 mm Hg.
Given that almost one-sixth of patients in our study were assigned
to the wrong CFI category when Pra was assumed to be negligible
or a fixed value, we believe that measurement of right atrial
pressure is imperative when calculating CFI.
The FFR and CFI were derived and validated with the inclusion
of right atrial pressure. Ignoring Pra in everyday practice debases
the fidelity of FFR and may lead to inappropriate therapy in some
cases. Similarly, assuming a fixed arbitrary Pra value leads to
substantial errors in CFI calculations. Therefore, right atrial
pressure should always be measured when calculating these phys-
iologic indexes. If the simplified index Pd/Pa is used, values
between 0.70 and 0.80 mandate recalculation of true FFR, after
measurement of Pra.
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Reticulated Platelets in Acute Coronary Syndrome: A Marker of Platelet Activity
To the Editor: Mean platelet volume (MPV) is elevated in
patients with acute coronary syndrome (ACS) (1) and is used as an
independent predictor of recurrent myocardial infarction and
cardiac death (2). Reticulated platelets (RP) are newly formed
platelets. They are larger in size, have higher granule content, and
selectively bind to thiazole orange dye (TO) that stains ribonucleic
acid and enhances its fluorescence signal (3). We then performed
this study to determine whether RP increase in ACS.
The study population consisted of 13 control subjects, 31
patients with unstable angina (UA), 25 patients with non–ST-
segment elevation myocardial infarction (NSTEMI), and 23 pa-
tients with ST segment elevation myocardial infarction (STEMI).
The Baylor College of Medicine Institutional Review Board
approved the study.
Volumes of 5 cc of blood were drawn before institution of
anticoagulation therapy into collection tubes containing ethyl-
enediaminetetraacetic acid (1.5 mg/ml). Complete blood count
and MPV were performed using an automated analyzer (Sysmex
HST, Kobe, Japan) within 30 min of blood collection. The range
of expected platelet volume in our laboratory is 7.4 to 10.4 fl for a
platelet count of 150 to 400 k/dl.
Reticulated platelets were prepared and measured according to
the previously described methods (4,5). To avoid nonspecific
labeling of RP, RNAse treatment was performed as a control for
measurement of %RP. Platelet-rich plasma was prepared by
centrifugation of collected blood in acid-citrate-dextrose (8.5/1.5,
v/v) at 170 g for 10 min at 22°C. The platelet-rich plasma was fixed
with 1% paraformaldehyde for 15 min divided into two aliquots.
One was incubated with 20 l/ml RNAse (Ambion, Austin,
Texas) for 30 min at 22°C. The second aliquot remained untreated
with RNAse and was used as a blank control. The specimen was
processed as indicated for platelet labeling.
Flow cytometric analysis was performed using a FACScalibur
(Becton Dickinson) flow cytometer. The GPlb-positive cells were
gated in a TO (FL1) versus PE (FL2) dot plot. A positive range
was set for platelets with fluorescence higher than 99% of the
TO-unstained control sample. Agate was set around the platelet
cloud, and 5,000 events were collected. Large TO-positive plate-
lets were assumed to represent RP. To define the frequency of RP,
a line with the same slope as the platelet cluster set to segregate
99% of the normal platelets below the line was established. The
placement of this line is admittedly arbitrary; however, it permits
a consistent and objective approach to the analysis of patients’
samples. In addition, in RNAse experiments, the placement of the
line appears to be appropriate. The true RP count was calculated
by subtraction of the TO-positive platelet count treated with
RNAse from the untreated TO platelet count. Figure 1 demon-
strates a fluorescence histogram of stained platelets with labeled
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Figure 1. (A) Platelets stained with GPlb in phosphate-buffered saline (PBS). The M1 marker was set to represent autofluorescent staining. (B) Platelets
stained with GPlb and thiazole orange. The M1 marker indicates platelets that stained positive for thiazole orange. (C) Platelets treated with RNAse and
subsequently stained with GPlb and thiazole orange. The M1 marker represents the reticulated platelets that are positive for thiazole orange.
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GPlb PE alone (Fig. 1A), GPlb PE and TO (Fig. 1B), and
RNAse-treated platelets stained with labeled GPlb PE and TO (Fig.
1C).
The data are expressed as mean  SD. Comparisons between
each of the four groups were analyzed by unpaired t test; compar-
isons among the four groups were also compared using one-way
analysis of variance with adjustment for multiple comparisons. A p
value 0.05 was considered statistically significant.
Baseline characteristics are displayed in Table 1. As shown,
there were no differences between the four groups, except for
history of myocardial infarction (p  0.011). The mean platelet
count and MPV increased among the groups (p  0.0001).
Percent of TO-positive platelets was 3.64  1.06 for control
subjects, 10.53  2.71 for patients with unstable angina, 15.99 
6.39 for patients with NSTEMI, and 18.94  4.89 for STEMI
subjects (p  0.0001). Similarly RNAse-treated TO-positive
platelets displayed a similar pattern (p  0.0001). The percentage
of RP was 11.9  4.57 in the STEMI subjects, 10.63  4.94 in
patients with NSTEMI, 8.39  2.49 in patients with unstable
angina, and 2.54  0.88 in the control subjects (p  0.0001).
Patients who presented with STEMI had significantly higher RP
compared with the UA group in paired group analysis (p 
0.00026 for STEMI). The correlation coefficient between tropo-
nin and RP count was 0.42 (p  0.05).
In this study, we demonstrated a significant increase in RP in
patients with AMI (NSTEMI or STEMI) and UA compared with
patients with stable angina. We also demonstrated an increase in
RP in patients with AMI compared with UA. Previous studies
have demonstrated similar findings in patients with cardio-embolic
stroke (6). Our data reconfirmed increased MPV in patients with
ACS, accompanied with a significant increase in platelet density as
evidenced by nonspecific binding to TO in RNAse-treated sam-
ples. Nonspecific TO binding has been shown to correlate with
platelet granularity (7).
Reticulated platelet analysis using TO and flow cytometry is a
convenient method for evaluating platelet kinetics in patients with
ACS. Using this method, platelets’ behavior is analyzed in their
physiologic milieu without activation. Our study suggests a novel
practical assay of platelet kinetics in ACS, which may have future
implications for risk stratification and antiplatelet therapy.
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Table 1. Baseline Characteristics of the Study Groups
Controls
(n  13)
UA
(n  31)
NSTEMI
(n  25)
STEMI
(n  23) p Value
Demographics
Age (yrs), mean  SD 56.0 11.3 59.1 8.7 59.6 9.8 55.6 9.2 0.35
Male 9 (69.2) 24 (77.4) 17 (68) 17 (73.9) 0.86
Risk factors
Diabetes 6 (46.2) 14 (45.2) 9 (36) 12 (52.2) 0.43
History of MI 3 (23) 3 (9.7) 7 (28) 9 (39.1) 0.01*
Hypertension 7 (53.8) 9 (29) 8 (32) 6 (26.1) 0.77
Dyslipidemia 8 (61) 12 (38.7) 10 (40) 14 (60.9) 0.79
Treatment
ASA 3 (23) 6 (19) 2 (8) 4 (17) 0.59
Beta-blocker 2 (15) 4 (13) 1 (4) 2 (9) 0.65
Cardiac enzymes (mean  SD)
Creatine kinase 23 5 103.3  87.5 660.0 550.1 2,403.3 1,138.2 0.0001*
Troponin-1 0.10 1.2 0.34 1.6 29.55 21.9 86.54 68.1 0.0001*
Hematologic variables (mean  SD)
Platelet count (109/l) 224.4  35.8 219.2 32.5 201.5 32.6 188.8 35.9 0.002*
Mean platelet volume 9.36  0.43 9.28 0.91 10.13 1.07 11.21 1.22 0.0001*
Values in parentheses are percentages. *Statistically significant difference exists between study subgroups.
ASA  acetylsalicylic acid; MI  myocardial infarction; NSTEMI  non–ST-segment elevation myocardial infarction; STEMI  ST-segment elevation myocardial
infarction; UA  unstable angina.
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